PMDA drug package insert
注射用タゴシッド200mg
PMDA Prescription drug · サノフィ株式会社 · package insert May 29, 2023
Key facts
| Brand names | 注射用タゴシッド200mg |
|---|---|
| Nonproprietary names | テイコプラニン |
| Companies | 製造販売元／サノフィ株式会社 |
| Product type | Prescription drug |
| Therapeutic category | グリコペプチド系抗生物質製剤 |
| Therapeutic category codes | 876119 |
| YJ codes | 6119401D1035 |
| Approval numbers | 21800AMX10418 |
| Package insert edition | 第2版 |
| Package insert date | May 29, 2023 |
| PMDA document key | 780069_6119401D1035_1 |
| PMDA company code | 780069 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: